Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent Manners
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Accumulating epidemiological evidence shows that obesity is associated with an increased risk of several types of adult cancers, including endometrial cancer. Chronic hyperinsulinemia, a typical hallmark of diabetes, is one of the leading factors responsible for the obesity-cancer connection. Numerous cellular and circulating factors are involved in the biochemical chain of events leading from hyperinsulinemia and insulin resistance to increased cancer risk and, eventually, tumor development. Metformin is an oral anti-diabetic drug of the biguanide family used for treatment of type 2 diabetes. Recently, metformin was shown to exhibit anti-proliferative effects in ovarian and Type I endometrial cancer, although the mechanisms responsible for this non-classical metformin action remain unclear. The insulin-like growth factors (IGFs) play a prominent role in cancer biology and their mechanisms of action are tightly interconnected with the insulin signaling pathways. Given the cross-talk between the insulin and IGF signaling pathways, the aim of this study was to examine the hypothesis that the anti-proliferative actions of metformin in uterine serous carcinoma (USC) are potentially mediated via suppression of the IGF-I receptor (IGF-IR) pathway. Our results show that metformin interacts with the IGF pathway, and induces apoptosis and inhibition of proliferation and migration of USC cell lines with both wild type and mutant p53. Taken together, our results suggest that metformin therapy could be a novel and attractive therapeutic approach for human USC, a highly aggressive variant of endometrial cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin is shown to decrease insulin and IGF-1 levels and downregulate IIS in cancer cells”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Sarfstein et al. 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sarfstein, R., Belfiore, A., & Werner, H. (2010) · Cancers · doi:10.3390/cancers2020233 · Cited by 31 · cited 2×
“USPC-1 and USPC-2 cells were transfected as previously described [28,29].”
BackgroundMethodSelf-citationRetractedp53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“Part of these, seemingly, paradoxical results can be explained by the fact that Ishikawa cells are known to have mutations in the ras protooncogene, p53 [45] and pTen tumor suppressor gene, leading to constitutive phosphorylation of AKT [46].”
ResultThe phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 2×
“Deregulation of this fine balance might lead to metabolic growth related diseases, resistance to apoptosis, and increased proliferation [55,56].”
BackgroundRole of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“In vitro and in vivo studies showed increased peripheral insulin sensitivity and cancer growth inhibition by Ampk activation [27].”
BackgroundDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · cited 1×
“This was associated with decreased AKT activation [33], which led to reduced mTOR activation [23,34].”
BackgroundInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059 · cited 2×
“This was associated with decreased AKT activation [33], which led to reduced mTOR activation [23,34].”
BackgroundGuba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739 · cited 1×
“cell proliferation in a number of experimental systems [12–15].”
BackgroundA Detergent‐trypsin method for the preparation of nuclei for flow cytometric DNA analysis
Vindeløv, L. L., Christensen, I. J., & Nissen, N. I. (1983) · Cytometry · doi:10.1002/cyto.990030503 · Cited by 1,639
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Deregulation of this fine balance might lead to metabolic growth related diseases, resistance to apoptosis, and increased proliferation [55,56].”
BackgroundObesity, endogenous hormones, and endometrial cancer risk: a synthetic review.
Kaaks, R., Lukanova, A., & Kurzer, M. S. (2002) · PubMed · Cited by 1,180
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Currie et al [41], in a retrospective cohort study, found that metformin treatment was associated with lower risk of cancer, compared to other glucose-lowering therapies.”
ResultNew Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996 · cited 1×
“For example, Libby et al [40], in an observational cohort study, found that metformin use was associated with 37% lower adjusted incidence of cancer.”
BackgroundJiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“In addition, improved response to chemotherapy was seen in diabetic breast cancer patients receiving metformin, as opposed to those not receiving the drug [42].”
BackgroundBhaskar, P. T., & Hay, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.03.020 · Cited by 798 · cited 1×
“Previous studies showed that metformin phosphorylates the inhibitory Ser(789) site of IRS-1 via Ampk activation [32].”
BackgroundThe rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Hidalgo, M., & Rowinsky, E. K. (2000) · Oncogene · doi:10.1038/sj.onc.1204091 · Cited by 582 · cited 1×
“cell proliferation in a number of experimental systems [12–15].”
BackgroundInsulin/IGF and target of rapamycin signaling: a TOR de force in growth control
Oldham, S., & Hafen, E. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)00042-9 · Cited by 552 · cited 1×
“Under normal circumstances, upstream receptor tyrosine kinases, especially the IGF-I pathway, regulate this pathway [57].”
BackgroundAlimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523 · cited 2×
“In vitro studies suggested that metformin inhibits cancer cell growth by activating adenosine monophosphate protein kinase (Ampk), by inactivating the mammalian target of rapamycin (mTOR), and also by decreasing the activity of the mTOR effector S6K1 [10,11].”
BackgroundStructure of the human insulin receptor gene and characterization of its promoter.
Seino, S., Seino, M., Nishi, S., & Bell, G. I. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.1.114 · Cited by 361 · cited 1×
“Antonio Brunetti, Catanzaro, Italy) includes the region from 22 bp to 21823 bp upstream of the translation initiation site [30].”
BackgroundCantrell, L. A., Zhou, C., Mendivil, A., Malloy, K. M., Gehrig, P. A., & Bae-Jump, V. L. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.024 · Cited by 331 · cited 5×
“In colon cancer cells, metformin was found to induce apoptosis in vitro only in cells lacking p53 [19].”
BackgroundInfluentialMetformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth
Rocha, G. Z., Dias, M. M., Ropelle, E. R., Osório-Costa, F., Rossato, F. A., Vercesi, A. E., Saad, M. J. A., & Carvalheira, J. B. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2243 · Cited by 305 · cited 1×
“Recent studies reported that metformin use was associated with a significant decrease in the incidence of cancer [9].”
BackgroundGunter, M. J., Hoover, D. R., Yu, H., Wassertheil-Smoller, S., Manson, J. E., Li, J., Harris, T. G., Rohan, T. E., Xue, X., Ho, G. Y. F., et al. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2686 · Cited by 267 · cited 1×
“an important role in the biology of endometrial cancer [17,25].”
BackgroundKorch, C., Spillman, M. A., Jackson, T. A., Jacobsen, B. M., Murphy, S. K., Lessey, B. A., Jordan, V. C., & Bradford, A. P. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.06.017 · Cited by 251 · cited 1×
“Unlike Ishikawa, ECC-1 cells are not well characterized but exhibit the same p53 mutation as Ishikawa cells [50].”
BackgroundZhuang, Y., & Miskimins, W. K. (2008) · Journal of Molecular Signaling · doi:10.1186/1750-2187-3-18 · Cited by 246 · cited 1×
“This prevents these proteins from binding to, and inhibiting the cyclin E/CDK2 complex, which promotes progression from G0/G1 to S phase of the cell cycle [53].”
BackgroundAssociation between adiponectin, insulin resistance, and endometrial cancer
Soliman, P. T., Wu, D., Tortolero‐Luna, G., Schmeler, K. M., Slomovitz, B. M., Bray, M. S., Gershenson, D. M., & Lu, K. H. (2006) · Cancer · doi:10.1002/cncr.21866 · Cited by 232 · cited 1×
“A number of studies have shown that patients with type 2 diabetes have an increased risk for certain types of cancer [5], including endometrial tumors [6].”
BackgroundZakikhani, M., Blouin, M.-J., Piura, E., & Pollak, M. N. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0763-9 · Cited by 213 · cited 1×
“This was associated with decreased AKT activation [33], which led to reduced mTOR activation [23,34].”
BackgroundFrost, P., Moatamed, F., Hoang, B., Shi, Y., Gera, J., Yan, H., Frost, P., Gibbons, J., & Lichtenstein, A. (2004) · Blood · doi:10.1182/blood-2004-03-1153 · Cited by 188
The insulin-like growth factor-I receptor as an oncogene
Werner, H., & Bruchim, I. (2009) · Archives of Physiology and Biochemistry · doi:10.1080/13813450902783106 · Cited by 183 · cited 3×
“Furthermore, a recent study reported that treatment with an mTOR inhibitor (WAY-129327) decreased endometrial proliferation, whereas mTOR activation was followed by loss of negative feedback to insulin receptor substrate-1 (IRS-1) during the early stages of cancer development [17].”
BackgroundInfluentialSelf-citationTargeting AMPK: A new therapeutic opportunity in breast cancer
Hadad, S. M., Fleming, S., & Thompson, A. M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.01.007 · Cited by 173 · cited 2×
“In vitro studies suggested that metformin inhibits cancer cell growth by activating adenosine monophosphate protein kinase (Ampk), by inactivating the mammalian target of rapamycin (mTOR), and also by decreasing the activity of the mTOR effector S6K1 [10,11].”
BackgroundHanna, R. K., Zhou, C., Malloy, K., Sun, L., Zhong, Y., Gehrig, P. A., & Bae-Jump, V. L. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.01.009 · Cited by 160 · cited 1×
“Furthermore, recent studies showed that metformin enhanced the sensitivity of type I endometrial cells to cisplatin and taxol chemotherapy [43,44].”
BackgroundXie, Y., Wang, Y., Yu, L., Hu, Q., Ji, L., Zhang, Y., & Liao, Q. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.12.006 · Cited by 150 · cited 2×
“Other studies revealed that metformin also induced a significant inhibition in proliferation, growth arrest and induction of apoptosis, and enhanced the sensitivity to chemotherapy in Type I endometrial cancer [19,20].”
BackgroundRyan, A. J., Susil, B. J., Jobling, T. W., & Oehler, M. K. (2005) · Cell and Tissue Research · doi:10.1007/s00441-005-1109-5 · Cited by 150
Uhrbom, L., Nerio, E., & Holland, E. C. (2004) · Nature Medicine · doi:10.1038/nm1120 · Cited by 146
Molecular Carcinogenesis of Endometrial Cancer
Liu, F.-S. (2007) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/s1028-4559(08)60102-3 · Cited by 145 · cited 1×
“Known risk factors for this disease include, in addition, obesity, hypertension, late menopause, and estrogen use [7].”
BackgroundZhao, H., Dupont, J., Yakar, S., Karas, M., & LeRoith, D. (2004) · Oncogene · doi:10.1038/sj.onc.1207162 · Cited by 142 · cited 1×
“pTen is known to downregulate IGF-II and IGF-IR expression in hepatoma and prostate cancer cells [48,49], suggesting that the expression of a constitutively-active AKT in Ishikawa cells may induce an increase in IGF-IR expression.”
BackgroundWerner, H. (2011) · Oncogene · doi:10.1038/onc.2011.447 · Cited by 131 · cited 1×
“Specifically, wild type p53 was shown to suppress IGF-IR promoter activity as well as endogenous IGF-IR mRNA levels whereas, in contrast, mutant forms of p53 enhanced IGF-IR gene expression [24].”
BackgroundSelf-citationChoi, S. H., Kim, Y. W., & Kim, S. G. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.011 · Cited by 121 · cited 1×
“Glycogen synthase kinase-3ß (GSK3ß) is a Ser/Thr kinase that has been identified as a regulator of glycogen metabolism [37].”
BackgroundAbnormalities in the NF‐κB family and related proteins in endometrial carcinoma
Pallarés, J., Martínez‐Guitarte, J., Dolcet, X., Llobet‐Navàs, D., Rué, M., Palacios, J., Prat, J., & Matías‐Guiu, X. (2004) · The Journal of Pathology · doi:10.1002/path.1666 · Cited by 115
Santin, A. D., Zhan, F., Canè, S., Bellone, S., Palmieri, M., Thomas, M., Burnett, A., Roman, J. J., Cannon, M. J., Shaughnessy, J. D., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602480 · Cited by 115 · cited 2×
“USPC-1 and USPC-2 cells are regarded as a validated model for USC [51].”
BackgroundLandman, G. W. D., van Hateren, K. J. J., Kleefstra, N., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc10-0979 · Cited by 101 · cited 1×
“A number of studies have shown that patients with type 2 diabetes have an increased risk for certain types of cancer [5], including endometrial tumors [6].”
BackgroundXing, D., & Orsulic, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502256102 · Cited by 100 · cited 1×
“Rapamycin effectively inhibits the growth of ovarian tumors that rely on AKT signaling for proliferation, while tumors with alternative survival pathways may require the inactivation of multiple individual pathways for successful treatment [16].”
BackgroundBost, F., Sahra, I. B., MARCHAND‐BRUSTEL, Y. L., & Tanti, J. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834d8155 · Cited by 100 · cited 1×
“, LNCaP, MCF-7) exhibited a similar sensitivity to metformin than p53-null cells [54].”
BackgroundDietary glycemic index, glycemic load and ovarian cancer risk:a case–control study in Italy
Augustin, L. S. A., Polesel, J., Bosetti, C., Kendall, C. W. C., Vecchia, C. L., Parpinel, M. T., Conti, E., Montella, M., Franceschi, S., Jenkins, D. J. A., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/dkg022 · Cited by 91 · cited 1×
“A correlation between hyperinsulinemia, insulin resistance, and ovarian cancer development was demonstrated by Augustin et al [26].”
BackgroundTargeting the IGF1 axis in cancer proliferation
Bruchim, I., Attias-Geva, Z., & Werner, H. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903201702 · Cited by 82
Self-citationBeurel, E., Kornprobst, M., Eggelpoël, M.-J. B.-V., Ruiz‐Ruiz, C., Cadoret, A., Capeau, J., & Desbois‐Mouthon, C. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.08.001 · Cited by 82
Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells
Jin, X., Gossett, D. R., Wang, S., Yang, D., Cao, Y., Chen, J. C., Guo, R., Reynolds, R. K., & Lin, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602214 · Cited by 81 · cited 12×
“Part of these, seemingly, paradoxical results can be explained by the fact that Ishikawa cells are known to have mutations in the ras protooncogene, p53 [45] and pTen tumor suppressor gene, leading to constitutive phosphorylation of AKT [46].”
ResultInfluentialMetformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression
Dong, L., Zhou, Q., Zhang, Z., Zhu, Y., Duan, T., & Feng, Y. (2012) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/j.1447-0756.2011.01839.x · Cited by 77 · cited 1×
“Furthermore, recent studies showed that metformin enhanced the sensitivity of type I endometrial cells to cisplatin and taxol chemotherapy [43,44].”
BackgroundManagement of endometrial cancer
Kitchener, H. C. (2006) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2006.03.046 · Cited by 71
Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer
Sarfstein, R., Maor, S., Reizner, N., Abramovitch, S., & Werner, H. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.03.018 · Cited by 64
Self-citationSong, J., Ren, P., Zhang, L., Wang, X. L., Chen, L., & Shen, Y. H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.086 · Cited by 62
Liu, S., Yu, S., Hasegawa, Y., LaPushin, R., Xu, H., Woodgett, J. R., Mills, G. B., & Fang, X. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408607200 · Cited by 53
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue
Ciaraldi, T. P., Oh, D. K., Christiansen, L., Nikoulina, S. E., Kong, A. P. S., Baxi, S. C., Mudaliar, S. R. D., & Henry, R. R. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00176.2006 · Cited by 52 · cited 3×
“In addition, studies have shown that GSK3 is implicated in both insulin action and adipogenesis [38].”
BackgroundInfluentialKiang, J. G., Bowman, P. D., Wu, B. W., Hampton, N., Kiang, A. G., Zhao, B., Juang, Y.-T., Atkins, J. L., & Tsokos, G. C. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00194.2004 · Cited by 49 · cited 1×
“The rationale for these measurements was the fact that both p53 and pTEN down-regulate IGF-IR levels [35,36], whereas Sp1 was identified as a potent IGF-IR transactivator [35].”
BackgroundKang-Park, S., Lee, Y. I., & Lee, Y. I. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00535-0 · Cited by 48 · cited 1×
“pTen is known to downregulate IGF-II and IGF-IR expression in hepatoma and prostate cancer cells [48,49], suggesting that the expression of a constitutively-active AKT in Ishikawa cells may induce an increase in IGF-IR expression.”
BackgroundReynolds, R. K., Hu, C., & Baker, V. V. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.5089 · Cited by 42 · cited 1×
“Interestingly, Ishikawa cells secrete IGF-II, but not IGF-I [47].”
BackgroundAttias-Geva, Z., Bentov, I., Kidron, D., Amichay, K., Sarfstein, R., Fishman, A., Bruchim, I., & Werner, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.014 · Cited by 40
Self-citationSarfstein, R., Bruchim, I., Fishman, A., & Werner, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024468 · Cited by 39 · cited 6×
“Wound-healing assays were performed as described previously [28].”
BackgroundMethodInfluentialSelf-citationAttias-Geva, Z., Bentov, I., Ludwig, D. L., Fishman, A., Bruchim, I., & Werner, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.02.019 · Cited by 37 · cited 1×
“In addition, USPC-1 cells express higher endogenous IGF-IR and IR protein and mRNA levels than USPC-2 cells [52].”
BackgroundSelf-citationFor debate: the pathophysiological significance of IGF-I receptor overexpression: new insights.
Werner, H. (2009) · PubMed · Cited by 24
Self-citation
Research works printed but not linked: 1
- Bruchim I, Attias Z, Werner H (2009) Targeting the IGF1 axis in cancer proliferation. Expert Opin Ther Targets 13: 1179– 1192. 19663648 · DOI
Cited by
Benefits of Metformin in Attenuating the Hallmarks of Aging
Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.001 · Cited by 766
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
“Metformin is reported to downregulate expression of insulin and IGF-1 receptors (230, 231) and reduces phosphorylation of insulin receptors (232) including IRS-1 (230, 233).”
BackgroundPolycystic ovary syndrome current status and future perspective
Naz, R. K. (2014) · Frontiers in Bioscience · doi:10.2741/e695 · Cited by 259
Wang, Y., Xu, W., Yan, Z., Zhao, W., Mi, J., Li, J., & Yan, H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0731-5 · Cited by 254
“In uterine serous carcinoma (USC), the antiproliferative action of metformin is mediated by suppression of the IGF-1 receptor pathway [20].”
Yan, L., Zhou, J., Gao, Y., Ghazal, S., Lu, L., Bellone, S., Yang, Y., Liu, N., Zhao, X., Santin, A. D., et al. (2015) · Oncogene · doi:10.1038/onc.2014.236 · Cited by 208
Metadata
- Authors
- Sarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., & Werner, H.
- Affiliations
- Tel Aviv University (IL)
- Meir Medical Center (IL)
- Corresponding author
- Werner, Haim
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-19
- Volume
- 8
- Issue
- 4
- Pages
- e61537
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3631250
- OpenAlex
- W2009665800
- Cited by
- 150
- References
- 58
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 14 · 2020: 14 · 2019: 14 · 2018: 11 · 2017: 10 · 2016: 16 · 2015: 11 · 2014: 22 · 2013: 3
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- metformin, uterine serous carcinoma, IGF-1 receptor, p53, apoptosis, cell proliferation, cell migration, endometrial cancer, hyperinsulinemia, biguanides
- MeSH terms
- Forkhead Box Protein O1, Glycogen Synthase Kinase 3 beta, Adenylate Kinase, Cell Cycle, Cell Movement, Cell Survival, Female, Humans, Insulin, Insulin-Like Growth Factor I, Metformin, Phosphorylation, Promoter Regions, Genetic, Receptor, Insulin, Uterine Neoplasms, Signal Transduction, Down-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Endometrial Neoplasms, Apoptosis, Receptor, IGF Type 1, Cystadenocarcinoma, Serous, Glycogen Synthase Kinase 3, Cell Line, Tumor, Cell Proliferation, Forkhead Transcription Factors, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.